The Experts below are selected from a list of 1671 Experts worldwide ranked by ideXlab platform
Marko Duvnjak - One of the best experts on this subject based on the ideXlab platform.
-
hepatoprotective effect of bpc 157 a 15 aminoacid peptide on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or ccl4 administration a comparative study with dopamine agonists and somatostatin
Life Sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Ivo Rotkvic, Branko Turkovic, Vjekoslav Jagic, Boris Mildner, Marko DuvnjakAbstract:The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+Hepatic Artery Ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
-
Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
Life sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Ivo Rotkvic, Branko Turkovic, Vjekoslav Jagic, Boris Mildner, Marko DuvnjakAbstract:The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+Hepatic Artery Ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
-
Hepatoprotective effect of BPC 157, a 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin
Life Sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Branko Turkovic, Boris Mildner, Ivo Rotkvić, Vjekoslav Jagić, Marko DuvnjakAbstract:Abstract The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct + Hepatic Artery Ligation 48 h-restraint stress and CCl 4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl 4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective eefect of BPC 157, possible clinical application in liver diseases is now warranted.
Jay L. Grosfeld - One of the best experts on this subject based on the ideXlab platform.
-
Experimental liver cancer: improved response after Hepatic Artery Ligation and infusion of tumor necrosis factor-alpha and interferon-gamma.
Surgery, 1995Co-Authors: Rong Yang, Qi Liu, Frederick J. Rescorla, Jay L. GrosfeldAbstract:Background. The aim of this study is to investigate whether regional infusion of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) could improve the therapeutic results of Hepatic Artery Ligation (HAL) on liver cancer in a rat model. Methods. Morris hepatoma 3924A was implanted intraHepatically in 50 ACI rats. Two weeks after tumor implantation, 40 rats underwent Hepatic Artery cannulation and Ligation. The cannula was connected to an infusion port implanted subcutaneously. Animals were then divided into four groups of 10 each to receive seven daily intraarterial injections of IFN-γ 100,000 IU/rat/day (HAL + IFN group), TNF-α 30 μg/rat/day (HAL + TNF group), IFN + TNF (HAL + IFN + TNF group), or normal saline solution (HAL group). The remaining 10 rats received a laparotomy only and served as untreated controls. Tumor volume, viable tumor area, and histopathology were assessed after 3 weeks. Results. The tumor growth was significantly retarded in the HAL group compared with the controls (tumor volume 683 ± 245 mm 3 vs 2424 ± 596 mm 3 , p < 0.05 ANOVA). HAL + TNF (221 ± 93 mm 3 ) and HAL + IFN + TNF groups (74 ± 31 mm 3 but not the HAL + IFN group (493 ± 164 mm 3 ), were much more effective than the HAL group in controlling tumor growth (p < 0.05). HAL + IFN + TNF achieved the best tumor control resulting in a 60% tumor-free rate (p < 0.05 vs all other groups). Conclusions. These data suggest that HAL combined with regional infusion of TNF-α and IFN-γ significantly reduces tumor growth in a rat liver model. This attractive concept of combined modality therapy may have utility in the clinical setting in instances of unresectable liver cancer.
-
Liver bacterial clearance following Hepatic Artery Ligation and portacaval shunt.
The Journal of surgical research, 1991Co-Authors: Schmuel Katz, Marcus A. Jimenez, William E. Lehmkuhler, Jay L. GrosfeldAbstract:The reticuloendothelial system (RES) plays an important role in removing bacteria, endotoxins, and immune complexes from the circulation. Hepatic phagocytosis accounts for more than 80% of RES function. The dual Hepatic blood supply (Hepatic Artery/portal vein) may be altered by pathologic states and surgical procedures. This study evaluates and compares the effect of Hepatic Artery Ligation and portacaval shunt on Hepatic trapping of viable Escherichia coli. Thirty rats were placed in three groups: Group I was composed of sham operated controls; Group II underwent end-to-side portacaval shunt (PCS); and in Group III, Hepatic Artery Ligation (HAL) was performed. At 2 weeks following the operation 10935S-radiolabeled viable E. coli were injected via the tail vein. At 10 min, bacterial distribution in the different organs was determined. Tissue samples were processed for liquid scintillation counting. The final distribution of bacteria was calculated from the input specific activity (dpm/bacteria) and expressed as the mean percentage of injected viable E. coli per gram of tissue and per organ weight. There was a significant decrease of bacterial trapping by the liver in rats following PCS (Group II), 45.0 ± 10.4% vs controls 77.1 ± 3.73% (P < 0.005). This was partially compensated for by a significant increase of bacterial trapping by the lung. The decreased clearance in PCS rats is due to a reduction in liver mass compared to that in controls. Bacterial localization in HAL (Group III) rats was similar to that in controls. These data show that PCS decreases Hepatic clearance and increases pulmonary localization of viable E. coli. This phagocytic dysfunction may contribute to increased susceptibility to infection following portacaval shunt.
Predrag Sikiric - One of the best experts on this subject based on the ideXlab platform.
-
hepatoprotective effect of bpc 157 a 15 aminoacid peptide on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or ccl4 administration a comparative study with dopamine agonists and somatostatin
Life Sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Ivo Rotkvic, Branko Turkovic, Vjekoslav Jagic, Boris Mildner, Marko DuvnjakAbstract:The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+Hepatic Artery Ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
-
Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
Life sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Ivo Rotkvic, Branko Turkovic, Vjekoslav Jagic, Boris Mildner, Marko DuvnjakAbstract:The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+Hepatic Artery Ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
-
Hepatoprotective effect of BPC 157, a 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and Hepatic Artery Ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin
Life Sciences, 1993Co-Authors: Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Rudolf Rucman, Marijan Petek, Branko Turkovic, Boris Mildner, Ivo Rotkvić, Vjekoslav Jagić, Marko DuvnjakAbstract:Abstract The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct + Hepatic Artery Ligation 48 h-restraint stress and CCl 4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + Hepatic Artery Ligation, 48 h-restraint stress, CCl 4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective eefect of BPC 157, possible clinical application in liver diseases is now warranted.
V. Varea - One of the best experts on this subject based on the ideXlab platform.
-
Sclerosing cholangitis secondary to Hepatic Artery Ligation after abdominal trauma.
European journal of gastroenterology & hepatology, 2005Co-Authors: Javier Martín De Carpi, Xavier Tarrado, V. VareaAbstract:Several causes have been postulated as responsible for secondary sclerosing cholangitis (SSC), mainly in adults, and, although in very different situations, ischaemia seems to be one of the most important factors. The term 'ischaemic cholangitis' has been used as a collective label for all these ischaemia-induced bile duct lesions. The biliary epithelium is dependent on arterial blood flow, unlike the Hepatic parenchyma, which receives a dual blood supply from the Hepatic Artery and the portal vein. This makes the biliary epithelium very susceptible to changes in arterial blood flow. We present one adolescent patient who developed SSC after abdominal trauma with hepatectomy and Ligation of the right Hepatic Artery. Different factors could have helped in the development of SSC in our patient (septicaemia, bile duct destruction, cholecystectomy) but right Hepatic Artery Ligation seems to be the most important aetiological factor in the development of secondary ischaemic cholangitis.
Larsolof Hafström - One of the best experts on this subject based on the ideXlab platform.
-
The influence of Hepatic Artery Ligation and of vasopressin on liver tumour blood flow in rats.
Journal of surgical oncology, 1992Co-Authors: Peter Naredi, Göran Carlsson, Bengt Gustavsson, Per Lindér, Stig Holmberg, Rigmor Söderberg, Lars Jacobsson, Larsolof HafströmAbstract:The blood flow in an experimental adenocarcinoma in the rat liver was determined with the 133Xe-washout technique before and after Hepatic Artery Ligation (HAL). There was an initial reduction of the washout of 50%. This was further reduced after 1 day by 50%, which was maintained for 7 days. Seven days after HAL or sham procedures the 133Xe-washout was of similar magnitude in the liver tumours, although after the sham procedure the tumours were larger (3.4 g vs. 1.5 g). The estimated tumour blood flow was then approximately 0.04 ml × min−1 × g−1. The influence on normal liver parenchyma of HAL was a reduction at 30 minutes, which was maintained for 7 days. Postacton®—a synthetic vasopressin—did not influence the 133Xe-washout in normal liver parenchyma in non-tumour, as well as in tumour-bearing animals. There was no influence of Postacton® on the 133Xe-washout in the liver tumours. Thirty minutes after HAL Postacton® gave a reduction of blood flow in normal liver parenchyma of tumour-bearing animals, which is thus only from the portal vein. In tumours Postacton® did not significantly reduce the tumour blood flow immediately after HAL. © 1992 Wiley-Liss, Inc.